Article info

Download PDFPDF

571 Penpulimab for relapsed/refractory (R/R) classical hodgkin's lymphoma (cHL): Extended follow-up of the multicenter, single-arm, phase 2 study
Free

Authors

Citation

Song Y, Zhou K, Jin C, et al
571 Penpulimab for relapsed/refractory (R/R) classical hodgkin's lymphoma (cHL): Extended follow-up of the multicenter, single-arm, phase 2 study

Publication history

  • First published November 7, 2022.
Online issue publication 
November 07, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.